- Home
- KMDA vs GLRE Comparison
KMDA vs GLRE Comparison
Compare KMDA & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- GLRE
- Stock Information
- Founded
- KMDA 1990
- GLRE 2004
- Country
- KMDA Israel
- GLRE Cayman Islands
- Employees
- KMDA N/A
- GLRE N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- GLRE Property-Casualty Insurers
- Sector
- KMDA Health Care
- GLRE Finance
- Exchange
- KMDA Nasdaq
- GLRE Nasdaq
- Market Cap
- KMDA 398.5M
- GLRE 439.8M
- IPO Year
- KMDA N/A
- GLRE 2007
- Fundamental
- Price
- KMDA $6.62
- GLRE $12.95
- Analyst Decision
- KMDA Strong Buy
- GLRE
- Analyst Count
- KMDA 2
- GLRE 0
- Target Price
- KMDA $13.00
- GLRE N/A
- AVG Volume (30 Days)
- KMDA 70.7K
- GLRE 122.2K
- Earning Date
- KMDA 11-10-2025
- GLRE 11-03-2025
- Dividend Yield
- KMDA 3.00%
- GLRE N/A
- EPS Growth
- KMDA 27.97
- GLRE N/A
- EPS
- KMDA 0.32
- GLRE N/A
- Revenue
- KMDA $169,517,000.00
- GLRE $661,540,000.00
- Revenue This Year
- KMDA $14.49
- GLRE N/A
- Revenue Next Year
- KMDA $10.12
- GLRE N/A
- P/E Ratio
- KMDA $20.13
- GLRE N/A
- Revenue Growth
- KMDA 9.67
- GLRE N/A
- 52 Week Low
- KMDA $5.54
- GLRE $11.57
- 52 Week High
- KMDA $9.16
- GLRE $15.47
- Technical
- Relative Strength Index (RSI)
- KMDA 42.74
- GLRE 63.63
- Support Level
- KMDA $6.66
- GLRE $11.57
- Resistance Level
- KMDA $6.93
- GLRE $12.41
- Average True Range (ATR)
- KMDA 0.17
- GLRE 0.29
- MACD
- KMDA -0.02
- GLRE 0.08
- Stochastic Oscillator
- KMDA 10.71
- GLRE 92.03
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.